NASDAQ:BIOS - BioScrip Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $3.61 +0.02 (+0.56 %) (As of 02/17/2019 04:00 PM ET)Previous Close$3.61Today's Range$3.57 - $3.6652-Week Range$2.31 - $4.14Volume407,959 shsAverage Volume615,083 shsMarket Capitalization$462.23 millionP/E Ratio-8.20Dividend YieldN/ABeta0.69 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email BioScrip, Inc. provides infusion solutions in the United States. It engages in the preparation, delivery, administration, and clinical monitoring of pharmaceutical treatments that are administered to a patient through intravenous, subcutaneous, intramuscular, intra-spinal, and enteral methods. The company is primarily involved in the intravenous administration of medications to treat a range of acute and chronic conditions, such as infections, nutritional deficiencies, immunologic and neurologic disorders, cancer, pain, and palliative care. It also offers home nursing products and services to patients suffering from chronic and acute medical conditions. The company offers its services at patient's homes, outpatient clinics, nursing facilities, physician's offices, and ambulatory infusion centers. It markets and sells its products and services through sales and marketing representatives, and payor relationships. The company was founded in 1993 and is based in Denver, Colorado. Receive BIOS News and Ratings via Email Sign-up to receive the latest news and ratings for BIOS and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Home health care services Sub-IndustryHealth Care Services SectorMedical Current SymbolNASDAQ:BIOS Previous Symbol CUSIP09069N10 Webwww.bioscrip.com Phone720-697-5200Debt Debt-to-Equity RatioN/A Current Ratio1.79 Quick Ratio1.55Price-To-Earnings Trailing P/E Ratio-8.20 Forward P/E Ratio-10.94 P/E GrowthN/A Sales & Book Value Annual Sales$817.19 million Price / Sales0.57 Cash FlowN/A Price / Cash FlowN/A Book Value($0.66) per share Price / Book-5.47Profitability EPS (Most Recent Fiscal Year)($0.44) Net Income$-64,190,000.00 Net Margins-7.50% Return on EquityN/A Return on Assets-8.91%Miscellaneous Employees2,154 Outstanding Shares128,041,000Market Cap$462.23 million OptionableOptionable BioScrip (NASDAQ:BIOS) Frequently Asked Questions What is BioScrip's stock symbol? BioScrip trades on the NASDAQ under the ticker symbol "BIOS." How were BioScrip's earnings last quarter? BioScrip Inc (NASDAQ:BIOS) issued its quarterly earnings data on Tuesday, August, 7th. The company reported ($0.14) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.10) by $0.04. The company had revenue of $175.79 million for the quarter, compared to the consensus estimate of $169 million. View BioScrip's Earnings History. When is BioScrip's next earnings date? BioScrip is scheduled to release their next quarterly earnings announcement on Thursday, March 14th 2019. View Earnings Estimates for BioScrip. What price target have analysts set for BIOS? 5 brokerages have issued 1 year target prices for BioScrip's stock. Their predictions range from $3.25 to $10.00. On average, they anticipate BioScrip's share price to reach $5.15 in the next year. This suggests a possible upside of 42.7% from the stock's current price. View Analyst Price Targets for BioScrip. What is the consensus analysts' recommendation for BioScrip? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioScrip in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for BioScrip. What are Wall Street analysts saying about BioScrip stock? Here are some recent quotes from research analysts about BioScrip stock: 1. According to Zacks Investment Research, "In the last-reported quarter, BioScrip's revenues getting affected by the impact of higher core product mix, including the impact of contract changes with UnitedHealthcare worries us. However, we are encouraged by the company’s progress in the third quarter, courtesy of its new multi-faceted CORE plan to improve its financial position. The company also expects to earn core revenues at Home Solutions and witness continued core growth. The company also took certain rigorous steps to revitalize its sales force in the reported quarter. These developments should further drive business growth in 2018. Overall, BioScrip has outperformed its industry in the past six months." (1/3/2019) 2. Barrington Research analysts commented, "We continue to rate BIOS shares an OUTPERFORM and our price target is $4. We arrive at our price target by attaching a 14x multiple to our 2019 adjusted EBITDA estimate. We assume approximately $550 million in net debt (including pfd stock) 12 months from now. Company Description BioScrip, Inc. is a leading national provider of infusion and home healthcare management solutions. BioScrip partners with healthcare providers, including physicians, hospital systems, skilled nursing facilities, and with healthcare payors to provide patients better access to high quality, efficient post‐acute care services. BioScrip operates with a commitment to bring infusion therapy services into the home or alternate‐site settings." (10/5/2018) Has BioScrip been receiving favorable news coverage? News stories about BIOS stock have trended somewhat positive recently, according to InfoTrie Sentiment. The research firm scores the sentiment of news coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. BioScrip earned a media sentiment score of 1.4 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 1.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the stock's share price in the next several days. Who are some of BioScrip's key competitors? Some companies that are related to BioScrip include Chemed (CHE), Amedisys (AMED), LHC Group (LHCG), Addus Homecare (ADUS), Civitas Solutions (CIVI) and New York Health Care (BBAL). Who are BioScrip's key executives? BioScrip's management team includes the folowing people: Mr. Daniel E. Greenleaf, CEO, Pres & Director (Age 54)Mr. Stephen M. Deitsch, Sr. VP, CFO & Treasurer (Age 46)Ms. Harriet Booker, Sr. VP & COO (Age 52)Ms. Jody Kepler, Sr. VP, Chief Compliance Officer (Age 49)Mr. John McMahon, Chief Accounting Officer, VP & Controller (Age 54) Who are BioScrip's major shareholders? BioScrip's stock is owned by a number of of institutional and retail investors. Top institutional investors include Venor Capital Management LP (10.04%), BlackRock Inc. (7.66%), Gabelli Funds LLC (5.55%), D. E. Shaw & Co. Inc. (2.96%), Diamond Hill Capital Management Inc. (2.34%) and Dimensional Fund Advisors LP (2.04%). Company insiders that own BioScrip stock include Coliseum Capital Management, L, Daniel E Greenleaf, Michael G Bronfein and Stephen Deitsch. View Institutional Ownership Trends for BioScrip. Which institutional investors are selling BioScrip stock? BIOS stock was sold by a variety of institutional investors in the last quarter, including Venor Capital Management LP, Gabelli Funds LLC, Diamond Hill Capital Management Inc., Alta Fundamental Advisers LLC, D. E. Shaw & Co. Inc., Millennium Management LLC, Bank of America Corp DE and MetLife Investment Advisors LLC. View Insider Buying and Selling for BioScrip. Which institutional investors are buying BioScrip stock? BIOS stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Two Sigma Investments LP, Perritt Capital Management Inc., Dimensional Fund Advisors LP, Geode Capital Management LLC, MUFG Securities EMEA plc, Tibra Equities Europe Ltd and Rothschild & Co. Asset Management US Inc.. Company insiders that have bought BioScrip stock in the last two years include Daniel E Greenleaf and Stephen Deitsch. View Insider Buying and Selling for BioScrip. How do I buy shares of BioScrip? Shares of BIOS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is BioScrip's stock price today? One share of BIOS stock can currently be purchased for approximately $3.61. How big of a company is BioScrip? BioScrip has a market capitalization of $462.23 million and generates $817.19 million in revenue each year. The company earns $-64,190,000.00 in net income (profit) each year or ($0.44) on an earnings per share basis. BioScrip employs 2,154 workers across the globe. What is BioScrip's official website? The official website for BioScrip is http://www.bioscrip.com. How can I contact BioScrip? BioScrip's mailing address is 1600 BROADWAY SUITE 700, DENVER CO, 80202. The company can be reached via phone at 720-697-5200 or via email at [email protected] MarketBeat Community Rating for BioScrip (NASDAQ BIOS)Community Ranking: 2.9 out of 5 ( )Outperform Votes: 260 (Vote Outperform)Underperform Votes: 189 (Vote Underperform)Total Votes: 449MarketBeat's community ratings are surveys of what our community members think about BioScrip and other stocks. Vote "Outperform" if you believe BIOS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BIOS will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 2/17/2019 by MarketBeat.com StaffFeatured Article: What are retained earnings?